Abstract |
Autologous hematopoietic stem cell transplantation is the standard therapy for refractory/relapsed aggressive lymphoma. The initial step of the procedure involves mobilization and collection of hematopoietic stem cells. G-CSF fails to achieve mobilization in 15-25% of lymphoma patients. Plerixafor is a novel CXCR4 antagonist that can promote mobilization. It has been used successfully in patients after the failure of G-CSF. It is reasonable to test whether plerixafor should become the mobilizing agent of choice in patients expected to exhibit difficulties in mobilization. We initiated a study to assess the use of plerixafor as a first-line stem cell mobilizer in 20 elderly or heavily pretreated patients with non-Hodgkin or Hodgkin lymphoma. The minimum defined CD34+ cell dose of ≥2 × 106 cells/kg was achieved by 90% of the patients, and for 83% of them with one apheresis procedure. The target CD34+ dose of ≥5 × 106 cells/kg was achieved by 70% of the patients. The median number of circulating CD34+ cells before and after plerixafor was 14.4 and 42.8 cells/μl, respectively. The post- plerixafor adverse events were mild. All patients promptly engrafted after high-dose chemotherapy treatment. We conclude that plerixafor administration is safe and efficient for upfront mobilization in lymphoma patients predicted to be poor mobilizers.
|
Authors | Ivetta Danylesko, Rina Sareli, Nira Varda-Bloom, Ronit Yerushalmi, Noga Shem-Tov, Avichai Shimoni, Arnon Nagler |
Journal | Acta haematologica
(Acta Haematol)
Vol. 135
Issue 1
Pg. 29-36
( 2016)
ISSN: 1421-9662 [Electronic] Switzerland |
PMID | 26303343
(Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2015 S. Karger AG, Basel. |
Chemical References |
- Anti-HIV Agents
- Benzylamines
- CXCR4 protein, human
- Cyclams
- Heterocyclic Compounds
- Receptors, CXCR4
- plerixafor
|
Topics |
- Adult
- Aged
- Anti-HIV Agents
(administration & dosage, adverse effects)
- Autografts
- Benzylamines
- Cyclams
- Female
- Hematopoietic Stem Cell Mobilization
(methods)
- Heterocyclic Compounds
(administration & dosage, adverse effects)
- Hodgkin Disease
(blood, therapy)
- Humans
- Lymphoma, Non-Hodgkin
(blood, therapy)
- Male
- Middle Aged
- Peripheral Blood Stem Cell Transplantation
- Pilot Projects
- Receptors, CXCR4
(antagonists & inhibitors)
|